Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of bimekizumab in moderate to severe chronic plaque psoriasis
2016-001891-31Phase 2Completed
- Sponsor
- UCB
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis and psoriasis comparing Bimekizumab dose-ranging arms with Placebo (2 arms). Primary endpoint: PASI 90 response at Week 12. Started Jul 2016; status: completed.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2016-001891-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001891-31.